Detalhe da pesquisa
1.
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
N Engl J Med
; 382(20): 1894-1905, 2020 05 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-32402160
2.
Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.
Lancet Oncol
; 22(7): 991-1001, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34051880
3.
Atezolizumab and Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: Pharmacokinetic and Safety Assessments Based on Hepatic Impairment Status and Geographic Region.
Liver Cancer
; 10(5): 485-499, 2021 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-34721510
4.
Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study.
Liver Cancer
; 10(4): 296-308, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-34414118